Astonea Labs IPO is a bookbuilding of ₹37.67 crores. The issue is entirely a fresh issue of 27.90 lakh shares.
Astonea Labs IPO opens for subscription on May 27, 2025 and closes on May 29, 2025. The allotment for the Astonea Labs IPO is expected to be finalized on Friday, May 30, 2025. Astonea Labs IPO will be list on BSE SME with a tentative listing date fixed as Tuesday, June 3, 2025.
Astonea Labs IPO price band is set at ₹128 to ₹135 per share. The minimum lot size for an application is 1000. The minimum amount of investment required by retail investors is ₹1,28,000. But it is suggested to the investor to bid at the cutoff price to avoid the oversubscription senerio, which is about to ₹1,35,000. The minimum lot size investment for HNI is 2 lots (2,000 shares) amounting to ₹2,70,000.
Oneview Corporate Advisors Pvt. Ltd. is the book-running lead manager of the Astonea Labs IPO, while Kfin Technologies Limited is the registrar for the issue.
Refer to Astonea Labs IPO RHP for detailed information.
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally.
The company manufactures and markets a variety of pharmaceutical and cosmetic products, including antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynecological issues, infections, and more.
The company offers skin, tooth, and hair care products in forms like gels, creams, and serums, and also trades packaging and raw materials for pharmaceutical and cosmetic industries, meeting industry standards.
The company engages in contract manufacturing of pharmaceutical and cosmetic products, markets its own brands "Glow Up" and "Regero," plans to launch "Avicel," and exports to countries like Iraq and Yemen.
Produts and Offerings:
- Products under our own brands: The company markets “Glow Up” skincare and “Regero” pharma products, offering diverse affordable solutions.
- Products under contract manufacturing: The company provides pharmaceutical and cosmetic products under contract manufacturing, primarily for domestic and export markets.
As of August 16, 2024, the company had 217 employees on payroll.
Competitive Strengths:
- Experienced management and dedicated employee base
- Scalable business model
- Wide and diverse range of product offerings
- Quality Service